Ki Deuk Wohlfert
Nurse Practitioner · Auburn, WANPI 1679610885
Payments from drug & device makers
Across 56 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$374
- AbbVie$235
- Bayer$121
- Boehringer Ingelheim$97
- Nestle Healthcare Nutrition Inc.$93
- Aimmune Therapeutics, Inc.$89
- plus $520 from 14 others
What the payments were for
- Food & beverage$1,20379%
- Education$32521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $374 |
| AbbVie | 9 | $235 |
| Bayer | 5 | $121 |
| Boehringer Ingelheim | 4 | $97 |
| Nestle Healthcare Nutrition Inc. | 4 | $93 |
| Aimmune Therapeutics, Inc. | 3 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $68 |
| Johnson & Johnson | 3 | $66 |
| Shield Therapeutics Inc | 3 | $62 |
| GSK | 2 | $47 |
| Pfizer | 2 | $45 |
| Lundbeck LLC | 2 | $42 |
| Lilly USA, LLC | 1 | $33 |
| Corcept Therapeutics | 1 | $33 |
| Fidia Pharma USA Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Abbott | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Amgen | 1 | $14 |
How this compares
$1,528 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 379 | $393,828 |
| ProliaDenosumab | 92 | $161,008 |
| ZenpepLipase/Protease/Amylase | 104 | $159,410 |
| CreonLipase/Protease/Amylase | 130 | $157,972 |
| JanuviaSitagliptin Phosphate | 102 | $118,840 |
| VascepaIcosapent Ethyl | 151 | $72,659 |
| MyrbetriqMirabegron | 80 | $61,425 |
| TradjentaLinagliptin | 38 | $45,100 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $45,029 |
| JanumetSitagliptin Phos/Metformin Hcl | 45 | $44,197 |
| RexultiBrexpiprazole | 27 | $42,268 |
| RestasisCyclosporine | 56 | $38,466 |
| EliquisApixaban | 44 | $37,199 |
| XareltoRivaroxaban | 55 | $35,218 |
| LinzessLinaclotide | 44 | $29,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $97 | $444,387429 claims |
| AbbVieCreon, Restasis, Linzess | $235 | $225,831230 claims |
| AmgenProlia | $14 | $161,00892 claims |
| Aimmune Therapeutics, Inc.Zenpep | $89 | $159,410104 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Shingrix | $47 | $75,609154 claims |
| Astellas Pharma US IncMyrbetriq | $374 | $61,42580 claims |
| PfizerEliquis | $45 | $37,19944 claims |
| Novo NordiskRybelsus, Ozempic | $22 | $36,06032 claims |
| Johnson & JohnsonXarelto | $66 | $35,21855 claims |
| Lilly USA, LLCTrulicity | $33 | $27,52325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Auburn
- Darla ChapmanSeattle$541K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Wayne ClarkYakima$232K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.